A B S T R A C T It is widely accepted that the neoplastic B cells from patients with chronic lymphocytic leukemia (CLL) respond poorly to common mitogens. The fungal metabolite cytochalasin B (0.5 ,ug/ml) is a weak mitogen for normal lymphocytes. However, when peripheral blood lymphocytes from 19 patients with CLL of B cell origin (B-CLL) were cultured with 0.5 Mg cytochalasin B/ml, significant new DNA synthesis (['4C]thymidine incorporation) occurred in 18. Stimulation indices with cytochalasin B varied widely (range = 1.9-28.2, mean ± SD = 10.6 ± 7.5; Acpm range = 1,157-153,818; n = 26) but in 11 cases exceeded those seen with concanavalin A (Con A), phytohemagglutinin, or pokeweed mitogen. In all 11, the mitogenic response to cytochalasin B exceeded that to pokeweed mitogen, which is believed to be a T celldependent B cell mitogen. In three cases, the responses to cytochalasin B were 8.6, 3.5, and 2.3 times greater than those to Con A. As with other mitogens, the DNA synthetic response to cytochalasin B was time and dose dependent. Peak thymidine incorporation occurred at 72-88 h and declined thereafter. Significant mitogenic effects were observed with 0.1-5 pig cytochalasin B/ml with a peak at 0.5-2 ,ug/ml. Stimulated DNA synthesis was abolished by 1 mM hydroxyurea. Cells from two patients with B-CLL were separated by rosetting with sheep erythrocytes (E). Depletion of E-rosette-positive cells from the CLL cell population abolished the response to Con A but did not affect the response to
INTRODUCTION
Chronic lymphocytic leukemia (CLL)' is a systemic proliferation of small, mature-appearing, long-lived lymphocytes (1) . Except for a small number of patients with well-defined clinical features and T cell antigens on their lymphocytes, most cases of CLL are of B cell origin (2, 3) . These CLL cells are characterized by small amounts of monoclonal surface immunoglobulin (SIg) and the presence of membrane HLA-DR framework antigen (Ia-like).
Relatively few CLL cells are actively dividing, and most appear to be resting in the Go phase of the cell cycle. Mitogenic plant lectins, which transform normal human peripheral blood lymphocytes and stimulate DNA synthesis, are relatively inactive with CLL cells (4) (5) (6) . These include concanavalin A (Con A) and phytohemagglutinin (PHA), which are T cell mitogens, and pokeweed mitogen (PWM), which is a T cell-dependent B cell mitogen. More (7, 8) .
During the course of investigations on the potentiating effect of cytochalasin B on the transformation of normal lymphocytes by mevalonic acid (9-12), we ' Abbreviations used in this paper: B-CLL, CLL of B-cell origin; CLL, chronic lymphocytic leukemia; Con A, concanavalin A; Acpm, difference between [2-'4C]thymidine incorporation (counts per minute) of cells in the presence and absence of mitogen; DMSO, dimethyl sulfoxide; E, sheep erythrocytes; LPS, lipopolysaccharide; PHA, phytohemagglutinin; PMA, phorbol myristate acetate; PWM, pokeweed mitogen; SI, stimulation index (cpm mitogen/cpm control); SIg, surface immunoglobulin. discovered that cytochalasin B by itself is a potent mitogen for malignant lymphocytes from patients with CLL. Cytochalasin B is a fungal macrolide metabolite that has been shown to have profound effects on neutrophil aggregation, degranulation, oxidative metabolism, microfilament formation, and chemotaxis, as well as on the transport of hexoses and hexosamine and possibly nucleosides into cells (13) (14) (15) (16) (17) . At low concentrations cytochalasin B also enhances the mitogenic response of normal lymphocytes to lectins (18, 19) . In this report, we show that cytochalasin B is itself a potent mitogen for CLL cells of B cell origin (B-CLL). (20) . Surface marker studies were performed with fluorescein-conjugated monospecific antisera and various commercial monoclonal antibodies (Ortho Diagnostic Systems, Raritan, NJ).
METHODS
Cell fractionation. Sheep erythrocyte rosette positive (E+) and negative (E-) lymphocyte populations were isolated from Ficoll-Hypaque interface cells (22) . E-rosettepositive cells were pelleted through Ficoll-Hypaque, and the lymphocytes were recovered after hypotonic lysis of the erythrocytes. The E-rosette-negative cells were recovered from the saline-Ficoll-Hypaque interface.
Cell cultures. (Table I) . Among the 18 responders, the stimulation indices (SI) varied widely (range = 1.9-28.2; mean±SD = 10.6±7.5; n = 26) as did the absolute increase in counts per minute (Acpm range = 1,157-153,818). Two patients were studied three times and four patients were studied twice and a significant mitogenic response to cytochalasin B was observed in each instance. In experiments with lymphocytes from 11 patients, the response to cytochalasin B exceeded that of the same cell suspension to either 50 jAg/ml Con A (six cases), 10 jig/ml PHA (six cases), or 0.5 jig/ml PWM (all 11 patients). With cells from eight patients the response to cytochalasin B exceeded that to 100 ng/ml PMA. In only one patient (D.M.) was the incorporation of ['4C]thymidine into cytochalasin B-treated lymphocytes not significantly greater than into control cells.
Dose-response. As has been shown with other lymphocyte mitogens, the mitogenic response of CLL cells to cytochalasin B is dose-dependent and time-dependent. Fig. 1 (15, 18) . In the presence of Con A, PHA, or periodate, however, low concentrations of cytochalasin B (0.1-1 ,ug/ml) will enhance the synthesis of DNA, the accumulation of cyclic AMP, the the turnover of phosphatidylinositol, the transport of amino acids, and the uptake of calcium in normal human lymphocytes (18) . At (18, 19) .
Of interest, cytochalasin A had little or no stimulatory effect on thymidine incorporation by B-CLL cells, although it is 10 times more potent than cytochalasin B in potentiating the response of normal lymphocytes to lectins (18) . That relatively minor structural alterations are important in the interaction of cytochalasin B with lymphocyte membranes has previously been suggested by Green et al. (18) , who found that dihydrocytochalasin B and the 'y-lactone derivative of cytochalasin B are inactive in potentiating the response of normal lymphocytes to lectins. Other important differences between cytochalasins A and B with respect to their effects on cellular behavior have been described (34) (35) (36) .
It has been shown that most or all of the high-affinity binding sites for cytochalasin B in lymphocytes are close to the cell surface (14) and that cytochalasin B alters stimulated membrane phospholipid metabolism, one of the earliest detectable changes in mitogen-activated lymphocytes (37) . Cytochalasin B (5-10 zg/ ml) also inhibits the usual "capping" reaction seen in stimulated lymphocytes, perhaps interacting with actin or myosin within contractile microfilaments (38) (39) (40) . In addition, cytochalasin B (3-10 ug/ml) blocks antigen-dependent binding of normal lymphocytes to macrophages and inhibits the binding of T cells to macrophages even in the absence of specific antigen (41) . Therefore, the differential mitogenic effect of cytochalasin B on B-CLL cells vs. normal lymphocytes may involve an interaction with the neoplastic cell membrane of the CLL cells through vestigial receptors normally involved in the immune mechanism.
Whereas the classical mitogens probably stimulate the normal T cell population in patients with CLL, our studies suggest that cytochalasin B stimulates preferentially the leukemic B cell population. Thus, cytochalasin B should be a better agent to use in the search for chromosomal abnormalities in mitogenstimulated CLL cells than other presently available stimuli. The ability to promote cell cycling in B-CLL cells with cytochalasin B in vitro may have important applications in further investigations of the cytogenetics and cell biology of this often indolent neoplasm.
